CORRECTION article

Front. Immunol., 25 November 2022

Sec. Cancer Immunity and Immunotherapy

Volume 13 - 2022 | https://doi.org/10.3389/fimmu.2022.1099835

Corrigendum: DCBLD1 Overexpression is associated with a poor prognosis in head and neck squamous cell carcinoma

  • LF

    Ling-ling Fu 1,2

  • MY

    Ming Yan 1,2

  • MM

    Min-Xian Ma 1

  • YL

    Yi Luo 1

  • MS

    Min Shao 1

  • MG

    Martin Gosau 2

  • RE

    Reinhard E. Friedrich 2

  • TV

    Tobias Vollkommer 2

  • HF

    Hong-chao Feng 1*

  • RS

    Ralf Smeets 2,3

  • 1. Department of Oral and Maxillofacial Surgery, Guiyang Hospital of Stomatology, Guiyang, China

  • 2. Department of Oral and Maxillofacial Surgery, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

  • 3. Department of Oral and Maxillofacial Surgery, Division of Regenerative Orofacial Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

In the published article, there was an error in affiliations 1 and 2. Instead of “1Department of Oral and Maxillofacial Surgery, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, 2Department of Oral and Maxillofacial Surgery, Guiyang Hospital of Stomatology, Guiyang, China, “, it should be “1Department of Oral and Maxillofacial Surgery, Guiyang Hospital of Stomatology, Guiyang, China, 2Department of Oral and Maxillofacial Surgery, University Medical Center Hamburg-Eppendorf, Hamburg, Germany,”

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is notguaranteed or endorsed by the publisher.

Summary

Keywords

DCBLD1, biomarker, immune infiltrates, prognosis, head and neck squamous cell carcinoma

Citation

Fu L, Yan M, Ma M-X, Luo Y, Shao M, Gosau M, Friedrich RE, Vollkommer T, Feng H and Smeets R (2022) Corrigendum: DCBLD1 Overexpression is associated with a poor prognosis in head and neck squamous cell carcinoma. Front. Immunol. 13:1099835. doi: 10.3389/fimmu.2022.1099835

Received

16 November 2022

Accepted

17 November 2022

Published

25 November 2022

Approved by

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Volume

13 - 2022

Updates

Copyright

*Correspondence: Hong-chao Feng,

†These authors have contributed equally to this work

This article was submitted to Cancer Immunity and Immunotherapy, a section of the journal Frontiers in Immunology

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Cite article

Copy to clipboard


Export citation file


Share article

Article metrics